NO20026011D0 - HMG-CoA-reduktase-inhibitorer og fremgangsmåte - Google Patents

HMG-CoA-reduktase-inhibitorer og fremgangsmåte

Info

Publication number: NO20026011D0
Authority: NO; Norway
Prior art keywords: hmg; coa reductase; reductase inhibitors; inhibitors; coa
Prior art date: 2000-06-15

Application number

NO20026011A

Other languages

English (en)

Other versions

NO20026011L (no

Inventor

Jeffrey A Robl

Bang-Chi Chen

Chong-Qing Sun

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-15

Filing date

2002-12-13

Publication date

2002-12-13

2002-12-13 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2002-12-13 Publication of NO20026011D0 publication Critical patent/NO20026011D0/no

2003-02-12 Publication of NO20026011L publication Critical patent/NO20026011L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/10—Aza-phenanthrenes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Virology (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
Hospice & Palliative Care (AREA)
AIDS & HIV (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Child & Adolescent Psychology (AREA)
Gynecology & Obstetrics (AREA)
Reproductive Health (AREA)

NO20026011A 2000-06-15 2002-12-13 HMG-CoA-reduktase-inhibitorer og fremgangsmåte NO20026011L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US21159400P	2000-06-15	2000-06-15
PCT/US2001/018868 WO2001096311A2 (en)	2000-06-15	2001-06-12	Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases

Publications (2)

Publication Number	Publication Date
NO20026011D0 true NO20026011D0 (no)	2002-12-13
NO20026011L NO20026011L (no)	2003-02-12

Family

ID=22787566

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20026011A NO20026011L (no)	2000-06-15	2002-12-13	HMG-CoA-reduktase-inhibitorer og fremgangsmåte

Country Status (20)

Country	Link
US (1)	US20020028826A1 (no)
EP (1)	EP1294696A2 (no)
JP (1)	JP2004503541A (no)
KR (1)	KR20030010720A (no)
CN (1)	CN1436174A (no)
AR (1)	AR028732A1 (no)
AU (1)	AU2001266860A1 (no)
BR (1)	BR0111571A (no)
CA (1)	CA2412979A1 (no)
CZ (1)	CZ20023931A3 (no)
EC (1)	ECSP024386A (no)
HU (1)	HUP0302955A3 (no)
IL (1)	IL152718A0 (no)
MX (1)	MXPA02012415A (no)
NO (1)	NO20026011L (no)
PE (1)	PE20011364A1 (no)
PL (1)	PL362477A1 (no)
UY (1)	UY26776A1 (no)
WO (1)	WO2001096311A2 (no)
ZA (1)	ZA200210102B (no)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20110196039A9 (en) *	1994-10-05	2011-08-11	Kaesemeyer Wayne H	Controlled release arginine formulations
CZ2003390A3 (en) *	2000-08-15	2004-03-17	Pfizer Products Inc.	Therapeutic combination of a cetp inhibitor and atorvastatin
ES2214169T1 (es) *	2001-06-06	2004-09-16	Bristol-Myers Squibb Company	Procedimiento de preparacion de sulfonas quirales dioles e inhibidores del dihidroxiacido hmg coa reductasa.
DE60219793T2 (de)	2001-07-11	2008-01-24	Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield	Verfahren zur Behandlung von Cytokin-Vermittelten Erkrankungen
WO2003024395A2 (en)	2001-09-14	2003-03-27	Tularik Inc.	Linked biaryl compounds
GB0205165D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205175D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205166D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205176D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205162D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205170D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
WO2003090723A1 (en) *	2002-04-23	2003-11-06	Bristol-Myers Squibb Company	Modified-release vasopeptidase inhibitor formulation, combinations and method
CN1681533A (zh) *	2002-07-18	2005-10-12	三共株式会社	用于治疗动脉硬化的药用组合物
US20050192245A1 (en) *	2002-07-18	2005-09-01	Sankyo Company, Limited	Medicinal composition for treating arteriosclerosis
CA2494061C (en) *	2002-07-31	2011-06-14	Wayne R. Danter	Protein tyrosine kinase inhibitors
GB0220885D0 (en) *	2002-09-09	2002-10-16	Novartis Ag	Organic compounds
AU2003273675A1 (en) *	2002-10-09	2004-05-04	Wayne R. Danter	Protein tyrosine kinase inhibitors
FR2848452B1 (fr) *	2002-12-12	2007-04-06	Aventis Pharma Sa	Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
CN1812983A (zh)	2003-05-30	2006-08-02	兰贝克赛实验室有限公司	取代的吡咯衍生物及其作为hmg－co抑制剂的用途
US20070161700A1 (en)	2004-12-28	2007-07-12	Kowa Company, Ltd.	Inhibitor for the formation of y-secretase complex
EP1729761A4 (en) *	2004-03-05	2008-09-03	Eisai Co Ltd	TREATMENT OF CADASIL WITH CHOLINESTERASE INHIBITORS
CA2562069A1 (en) *	2004-04-14	2005-10-27	Warner-Lambert Company Llc	Therapeutic combination for treatment of alzheimers disease
EP1750862B1 (en) *	2004-06-04	2011-01-05	Teva Pharmaceutical Industries Ltd.	Pharmaceutical composition containing irbesartan
WO2006110882A2 (en) *	2005-04-12	2006-10-19	Psivida Inc.	Hmgcoa reductase inhibitor codrugs and uses thereof
EP1909848A2 (en) *	2005-08-01	2008-04-16	PSivida Inc.	HMGCoA REDUCTASE INHIBITOR CODRUGS AND USES THEREOF
SG166829A1 (en) *	2005-11-08	2010-12-29	Ranbaxy Lab Ltd	Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
CN103751781A (zh) *	2006-02-07	2014-04-30	持田制药株式会社	预防中风复发的组合物
NZ571465A (en) *	2006-02-27	2011-09-30	Targeted Molecular Diagnostics Llc	Compositions and methods for reducing cellular fat and for predicting cardiac toxicity and upon treatment with tyrosine kinase inhibitors
US8124622B2 (en) *	2006-03-29	2012-02-28	Kowa Co., Ltd.	Triglyceride-lowering agent and hyperinsulinism-ameliorating agent
WO2008059519A2 (en) *	2006-09-25	2008-05-22	Glenmark Pharmaceuticals Limited	A process for the preparation of intermediates of rosuvastatin
JP5571387B2 (ja)	2007-01-11	2014-08-13	クリティカル・アウトカム・テクノロジーズ・インコーポレイテッド	癌の治療のための化合物および方法
US8404275B2 (en) *	2007-07-01	2013-03-26	Vitalis Llc	Combination tablet with chewable outer layer
KR100900044B1 (ko) *	2007-07-05	2009-06-01	한국식품연구원	3-하이드록시-3-메틸글루타릴 보조효소 ａ 환원효소 저해용펩타이드 및 이를 함유하는 고콜레스테롤로 인한 심장질환 및 심혈관계 질환 치료제
TWI432195B (zh)	2007-10-03	2014-04-01	Kowa Co	神經細胞死亡抑制劑
US8466151B2 (en)	2007-12-26	2013-06-18	Critical Outcome Technologies, Inc.	Compounds and method for treatment of cancer
CA2730890C (en)	2008-07-17	2018-05-15	Critical Outcome Technologies Inc.	Thiosemicarbazone inhibitor compounds and cancer treatment methods
KR101104335B1 (ko) *	2009-03-06	2012-01-16	가톨릭대학교 산학협력단	알카노일화된 히알루론산으로 형성된 나노입자 및 그 제조방법
EP2552915B1 (en)	2010-04-01	2017-07-19	Critical Outcome Technologies Inc.	Compounds for the treatment of hiv
MX2013000824A (es) *	2010-07-21	2013-10-28	Nucitec Sa De Cv	Forma de dosificacion diaria unica para la prevencion y tratamiento del sindrome metabolico.
US8877221B2 (en)	2010-10-27	2014-11-04	Warsaw Orthopedic, Inc.	Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
US9107983B2 (en)	2010-10-27	2015-08-18	Warsaw Orthopedic, Inc.	Osteoconductive matrices comprising statins
WO2012098049A1 (en)	2011-01-18	2012-07-26	Dsm Sinochem Pharmaceuticals Netherlands B.V.	Process for the preparation of statins in the presence of base
EP2665721B1 (en) *	2011-01-18	2015-07-08	DSM Sinochem Pharmaceuticals Netherlands B.V.	Methyltetrazole sulfides and sulfones
CN103328470A (zh) *	2011-01-18	2013-09-25	中化帝斯曼制药有限公司荷兰公司	制备二醇砜的方法
US9308190B2 (en)	2011-06-06	2016-04-12	Warsaw Orthopedic, Inc.	Methods and compositions to enhance bone growth comprising a statin
US9226891B2 (en)	2011-10-28	2016-01-05	Vitalis Llc	Anti-flush compositions
CN103987705B (zh)	2011-12-09	2015-09-30	中化帝斯曼制药有限公司荷兰公司	制备他汀含硫前体的方法
CN103974946B (zh)	2011-12-09	2017-09-29	中化帝斯曼制药有限公司荷兰公司	制备他汀前体的方法
JP6041985B2 (ja) *	2012-06-08	2016-12-14	ミレファインケミカルカンパニーリミテッド	結晶型ｔ−ブチル２−［（４Ｒ，６Ｓ）−６−ホルミル−２，２−ジメチル−１，３−ジオキサン−４−イル］アセテート及びその製造方法
US8652527B1 (en)	2013-03-13	2014-02-18	Upsher-Smith Laboratories, Inc	Extended-release topiramate capsules
US9101545B2 (en)	2013-03-15	2015-08-11	Upsher-Smith Laboratories, Inc.	Extended-release topiramate capsules
CN112159403B (zh)	2020-09-30	2022-04-15	复旦大学	一种用于合成他汀类药物的关键中间体的制备方法
CN114394961A (zh) *	2021-12-24	2022-04-26	江苏阿尔法药业股份有限公司	用臭氧做氧化剂制备瑞舒伐他汀钙中间体的方法
CN114213350B (zh) *	2021-12-29	2024-03-19	江苏福瑞康泰药业有限公司	一种他汀类药物中间体的制备方法
CN114437052B (zh) *	2021-12-31	2024-03-29	江苏阿尔法集团福瑞药业(宿迁)有限公司	一种利用连续流微通道反应器合成他汀类药物中间体的方法
CN114601039A (zh) *	2022-03-16	2022-06-10	江苏省农业科学院	一种提高热应激下绵羊发情率和受胎率的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5506219A (en) *	1988-08-29	1996-04-09	E. R. Squibb & Sons, Inc.	Pyridine anchors for HMG-CoA reductase inhibitors

2001
- 2001-06-06 US US09/875,218 patent/US20020028826A1/en not_active Abandoned
- 2001-06-12 IL IL15271801A patent/IL152718A0/xx unknown
- 2001-06-12 EP EP01944449A patent/EP1294696A2/en not_active Withdrawn
- 2001-06-12 PL PL01362477A patent/PL362477A1/xx not_active Application Discontinuation
- 2001-06-12 HU HU0302955A patent/HUP0302955A3/hu unknown
- 2001-06-12 CN CN01811219A patent/CN1436174A/zh active Pending
- 2001-06-12 WO PCT/US2001/018868 patent/WO2001096311A2/en not_active Ceased
- 2001-06-12 BR BR0111571-5A patent/BR0111571A/pt not_active IP Right Cessation
- 2001-06-12 AU AU2001266860A patent/AU2001266860A1/en not_active Abandoned
- 2001-06-12 CA CA002412979A patent/CA2412979A1/en not_active Abandoned
- 2001-06-12 CZ CZ20023931A patent/CZ20023931A3/cs unknown
- 2001-06-12 KR KR1020027017087A patent/KR20030010720A/ko not_active Withdrawn
- 2001-06-12 JP JP2002510454A patent/JP2004503541A/ja active Pending
- 2001-06-12 MX MXPA02012415A patent/MXPA02012415A/es unknown
- 2001-06-15 PE PE2001000579A patent/PE20011364A1/es not_active Application Discontinuation
- 2001-06-15 UY UY26776A patent/UY26776A1/es not_active Application Discontinuation
- 2001-06-15 AR ARP010102885A patent/AR028732A1/es not_active Application Discontinuation
2002
- 2002-12-12 ZA ZA200210102A patent/ZA200210102B/en unknown
- 2002-12-12 EC EC2002004386A patent/ECSP024386A/es unknown
- 2002-12-13 NO NO20026011A patent/NO20026011L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
UY26776A1 (es)	2002-01-31
ECSP024386A (es)	2003-03-10
HUP0302955A2 (hu)	2003-12-29
BR0111571A (pt)	2003-07-01
EP1294696A2 (en)	2003-03-26
AU2001266860A1 (en)	2001-12-24
CZ20023931A3 (cs)	2003-03-12
KR20030010720A (ko)	2003-02-05
JP2004503541A (ja)	2004-02-05
NO20026011L (no)	2003-02-12
US20020028826A1 (en)	2002-03-07
PE20011364A1 (es)	2002-02-27
HUP0302955A3 (en)	2005-08-29
AR028732A1 (es)	2003-05-21
PL362477A1 (en)	2004-11-02
IL152718A0 (en)	2003-06-24
WO2001096311A3 (en)	2002-07-11
MXPA02012415A (es)	2003-06-06
WO2001096311A2 (en)	2001-12-20
CN1436174A (zh)	2003-08-13
ZA200210102B (en)	2004-03-12
CA2412979A1 (en)	2001-12-20

Publication	Publication Date	Title
NO20026012D0 (no)	2002-12-13	HMG-CoA-reduktase-inhibitorer og metode
NO20026011D0 (no)	2002-12-13	HMG-CoA-reduktase-inhibitorer og fremgangsmåte
NO20014823L (no)	2001-10-04	Heterocyklus-holdige bifenyl-aP2-inhibitorer og metode
ATE286049T1 (de)	2005-01-15	Pyridazinonaldose reductase inhibitoren
EP1684754A4 (en)	2010-05-12	HMG COA REDUCTASE INHIBITORS AND METHOD
NO20032668L (no)	2003-06-12	Gyraseinhibitorer og anvendelser derav
NO20044915L (no)	2004-12-16	C-aryl-glukosid SGLT2 inhibitorer og metode
NO20024295D0 (no)	2002-09-09	Cyclopropyl-kondenserte pyrrolidin-baserte inhibitorer av dipeptidyl peptidase IV og fremgangsmåte
DE60211317D1 (de)	2006-06-14	Rho-kinase inhibitoren
DE60218138D1 (de)	2007-03-29	Rho-kinase inhibitoren
DK1223918T3 (da)	2003-04-28	Farmaceutiske præparater omfattende en HMG-CoA-reductaseinhibitor
NO20025416L (no)	2003-05-14	System og fremgangsmåte ved ekspanderbar komplettering
ATE269701T1 (de)	2004-07-15	Gyrase-inhibitoren und ihre verwendung
NO20015492D0 (no)	2001-11-09	Fremgangsmåte og anordning for flersidig forbindelse
NO20052779D0 (no)	2005-06-08	Doseringsformer omfattende en CETP-inhibitor og en HMG-CoA-reduktaseinhibitor.
NO20040865L (no)	2004-05-25	Friksjon reduserende sammensetning og metode
NO20026054D0 (no)	2002-12-17	Akustisk loggeapparat og fremgangsmåte
IS6691A (is)	2003-01-20	Aðferð og algoritmi til að greina mRNA tjáningu
NO20033854D0 (no)	2003-09-01	N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
ATE502118T1 (de)	2011-04-15	Amplifizierungsverfahren
FI20000715A0 (fi)	2000-03-28	Ryhmätyömenetelmä ja -järjestelmä
DE60231591D1 (de)	2009-04-30	Aufzeichnungsvorrichtung und -verfahren
DE60135813D1 (de)	2008-10-30	CDMA Empfangsgerät und -verfahren
AU6045801A (en)	2001-12-11	Inhibitor function check method and apparatus
AU5258701A (en)	2001-11-12	Method of searching for arteriosclerosis inhibitors and shrinkers

Legal Events

Date	Code	Title	Description
2006-01-30	FC2A	Withdrawal, rejection or dismissal of laid open patent application